phentermine and pulmonary hypertension

Phentermine is a medication frequently prescribed for obesity, while pulmonary arterial hypertension (PAH) is a cardiac condition marked by elevated pressure in the pulmonary arteries. Typically, there is a recognized link between phentermine and PAH, as the long-term use of phentermine, an appetite suppressant, could potentially raise the risk of PAH.

Phentermine's mechanism of action involves stimulating the central nervous system to decrease appetite, which aids in weight reduction. However, this stimulation might also impact the cardiovascular system, leading to increased pulmonary artery pressure. Moreover, phentermine can also induce valvular heart disease, which may worsen the symptoms of PAH. Consequently, when administering phentermine for obesity, it is crucial to vigilantly monitor the patient's cardiovascular health and perform regular assessments.

For patients on phentermine, it is advised to adhere to medical guidance and periodically check blood pressure and cardiac function. Should symptoms such as shortness of breath, chest pain, or syncope arise, immediate medical consultation is imperative. Additionally, patients should adhere to a healthy lifestyle, including a balanced diet, regular exercise, abstaining from smoking, and moderating alcohol consumption, to mitigate the risk of PAH. In conclusion, when treating obesity with phentermine, the potential side effects must be approached with caution, and medication should be taken under the supervision of a healthcare provider.